Health Care | Pharmaceuticals, Biotechnology & Life Sciences | Biotechnology
NASDAQ | Common Stock
Ra Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, develops therapeutics for the treatment of diseases caused by excessive or uncontrolled activation of the complement system.
The company's peptide chemistry platform enables the production of synthetic macrocyclic peptides that combine the diversity and specificity of antibodies with the pharmacological properties of small molecules.
Its lead product candidate is Zilucoplan, an injection into the tissue under the skin that has completed Phase II clinical trial for the treatment of generalized myasthenia gravis (gMG); has completed Phase II clinical trial for treating paroxysmal nocturnal hemoglobinuria (PNH); and has completed Phase Ib clinical trial to treat patients with renal impairment.
The company's pre-clinical programs include Factor D inhibition for treating C3 glomerulonephritis and dense deposit disease; and inhibitors of other complement factors for renal, autoimmune, and central nervous system diseases.
It has collaboration and license agreement with Merck & Co., Inc. to identify orally available cyclic peptides for non-complement cardiovascular targets, and provide research and development services.
Ra Pharmaceuticals, Inc. was founded in 2008 and is headquartered in Cambridge, Massachusetts.
As of April 2, 2020, Ra Pharmaceuticals, Inc. operates as a subsidiary of UCB SA.
| Reported date | EPSChange YoY | EstimateSurprise |
|---|---|---|
| Dec 31, 19 | -0.79 Decreased by -66.77% | -0.63 Decreased by -25.40% |
| Sep 30, 19 | -0.55 Decreased by -7.80% | -0.50 Decreased by -10.00% |
| Jun 30, 19 | -0.52 Decreased by -6.69% | -0.49 Decreased by -6.12% |
| Mar 31, 19 | -0.45 Increased by +25.69% | -0.48 Increased by +6.25% |
| Mar 7, 19 | -0.47 Increased by +29.21% | -0.52 Increased by +8.90% |
| Nov 8, 18 | -0.51 Increased by +24.47% | -0.49 Decreased by -4.12% |
| Aug 8, 18 | -0.49 Increased by +13.10% | -0.55 Increased by +11.38% |
| May 10, 18 | -0.61 Decreased by -20.21% | -0.56 Decreased by -8.14% |
| Fiscal ending date | RevenueChange YoY | IncomeChange YoY | ProfitChange YoY |
|---|---|---|---|
| Dec 31, 19 | 0.00 Decreased by -100.00% | -36.78 M Decreased by -127.09% | Decreased by N/A% Decreased by N/A% |
| Sep 30, 19 | 3.00 M Increased by +N/A% | -24.98 M Decreased by -51.33% | Decreased by -832.50% Decreased by N/A% |
| Jun 30, 19 | 0.00 Decreased by N/A% | -21.90 M Decreased by -39.06% | Decreased by N/A% Decreased by N/A% |
| Mar 31, 19 | 0.00 Decreased by N/A% | -19.04 M Decreased by -15.40% | Decreased by N/A% Decreased by N/A% |
| Dec 31, 18 | 2.50 M Increased by +N/A% | -16.20 M Increased by +58.65% | Decreased by -647.80% Decreased by N/A% |
| Sep 30, 18 | 0.00 Decreased by N/A% | -16.50 M Decreased by -531.85% | Decreased by N/A% Decreased by N/A% |
| Jun 30, 18 | 0.00 Decreased by N/A% | -15.75 M Decreased by -1.11 K% | Decreased by N/A% Decreased by N/A% |
| Mar 31, 18 | 0.00 Decreased by N/A% | -16.50 M Decreased by -45.23% | Decreased by N/A% Decreased by N/A% |